<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H326E4DD0675348AEB8E656F8E813BD4C" public-private="public" key="H" bill-type="olc">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 3010 IH: No Handouts for Drug Advertisements Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-04-24</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
<congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session>
<legis-num display="yes">H. R. 3010</legis-num>
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
<action display="yes">
<action-date date="20250424">April 24, 2025</action-date>
<action-desc><sponsor name-id="M001210">Mr. Murphy</sponsor> (for himself, <cosponsor name-id="C001119">Ms. Craig</cosponsor>, <cosponsor name-id="B001323">Mr. Begich</cosponsor>, and <cosponsor name-id="S001221">Ms. Scholten</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name></action-desc>
</action>
<legis-type>A BILL</legis-type>
<official-title display="yes">To amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for certain drugs.</official-title>
</form>
<legis-body id="HC6B97412019B4E9B9F17D2E7EB6FDA83" style="OLC">
<section id="HBFDA60D8AD634273A04CD8921497F8C5" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>No Handouts for Drug Advertisements Act</short-title></quote>.</text></section> <section id="H81340EE7F5C649BC86BBDCAD1F74915F" section-type="subsequent-section"><enum>2.</enum><header>Disallowance of deduction for advertising and promotional expenses for certain drugs</header> <subsection id="HC17FC1CEFA2848958005BEE7BF1D67AA"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Part IX of subchapter B of chapter 1 of subtitle A of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:</text>
<quoted-block style="OLC" display-inline="no-display-inline" id="HA56D72974DB240AD9F4CE4448267824B">
<section id="H2E60A0DF36A94F81B42365DEC296D895"><enum>280I.</enum><header>Disallowance of deduction for direct-to-consumer advertising of certain drugs</header>
<subsection id="HCDB68C9EC68A4B6EA0103FD023907A8D"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">No deduction shall be allowed under this chapter for expenses relating to direct-to-consumer advertising of covered drugs for any taxable year.</text></subsection> <subsection id="H6DFFC58969CB4925BE59483EA7C7AB05"><enum>(b)</enum><header>Direct-to-Consumer advertising</header><text>For purposes of this section—</text>
<paragraph id="H94154F63B24F40BD96D37081C4761E0B" commented="no" display-inline="no-display-inline"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The term <term>direct-to-consumer advertising</term> means any dissemination, by or on behalf of a covered entity, of an advertisement which—</text> <subparagraph id="H7E8C7AD438F44352BF05C3609C999004"><enum>(A)</enum><text>is in regard to a covered drug, and</text></subparagraph>
<subparagraph id="HE789F4CC4B8A4A93A7D822B8C8FFFADA"><enum>(B)</enum><text>primarily targeted to the general public, including through—</text> <clause id="H05D2DC95351948E9B51836C4FA639E82"><enum>(i)</enum><text>broadcasting through media such as radio, television, and telephone communication systems, direct mail, and billboards, and</text></clause>
<clause id="H9D03C152F996411EA8343138118AC404"><enum>(ii)</enum><text>dissemination on the Internet or through digital platforms (including social media, mobile media, web applications, digital applications, mobile applications, and electronic applications).</text></clause></subparagraph></paragraph> <paragraph id="H56AE7E663AA94B1BB8DE00B4DEF439A1" commented="no" display-inline="no-display-inline"><enum>(2)</enum><header>Exception</header><text display-inline="yes-display-inline">Such term shall not include an advertisement made through publication in journals and other periodicals.</text></paragraph>
<paragraph id="H84A5D5CEA7ED49E2A3C6AB749CE0FF52" commented="no" display-inline="no-display-inline"><enum>(3)</enum><header>Other terms</header><text display-inline="yes-display-inline">For purposes of this subsection—</text> <subparagraph id="HBC7CC6968C2C48BABEF112E3C9EBE243"><enum>(A)</enum><header>Covered entity</header><text>The term <term>covered entity</term> means—</text>
<clause id="H1FB7AA87939A43D6A4C8C6C56AA1E4AB"><enum>(i)</enum><text>a sponsor of a prescription drug product (as such term is defined in section 735(3) of the Federal Food, Drug, and Cosmetic Act), or</text></clause> <clause id="H0301D3589D724FFE818D4D5F9C948F1A"><enum>(ii)</enum><text>a person that owns an outsourcing facility (as such term is defined in section 503B(d)(4) of such Act), either directly or indirectly through a subsidiary.</text></clause></subparagraph>
<subparagraph id="H15A63AF60E534DA48FCEB09DBD959A91"><enum>(B)</enum><header>Covered drug</header><text>The term <term>covered drug</term> means—</text> <clause id="H9FC91A6D585B4C65A680A8E3B68D4498"><enum>(i)</enum><text>a prescription drug product (as such term is defined in section 735(3) of the Federal Food, Drug, and Cosmetic Act), or</text></clause>
<clause id="H84119AE5B7C7459B84FA9419BCE2BE4D"><enum>(ii)</enum><text>a drug compounded in accordance with section 503A or 503B of such Act.</text></clause></subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="H082485C77D914BBBB3D049E24D265A25"><enum>(b)</enum><header>Conforming amendment</header><text>The table of sections for such part IX of the Internal Revenue Code of 1986 is amended by adding after the item relating to section 280H the following new item:</text>
<quoted-block style="OLC" id="HEAAD05C0D56145A3980B2C677AD0AE40">
<toc>
<toc-entry level="section" idref="H2E60A0DF36A94F81B42365DEC296D895">Sec. 280I. Disallowance of deduction for direct-to-consumer advertising of certain drugs.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></subsection>
<subsection id="H5A13DCED590843EDBEC6531E3007386C"><enum>(c)</enum><header>Effective date</header><text>The amendments made by this section shall apply to amounts paid or incurred after the date of the enactment of this Act, in taxable years ending after such date.</text></subsection></section> </legis-body> </bill> 

